Originator of Entrectinib and other innovative molecules


Fully integrated platform for R&D value chain


“Shaping oncology innovation”. Our commitment.


Proved track record, high quality standards and fully compliant services.


High value organization for oncology innovation

Delivering innovative drugs and high quality CRO e CDMO services


The mission of NMS Group is to discover and develop new molecules and therapeutic strategies, contributing to shape the future of cancer care. Thanks to its unique fully integrated R&D chain, the Group is also committed in offering high quality pre-clinical, clinical and production services at a global level.
The vast scientific heritage of internal skills, technology and experience represents our excellence and the basis for achieving our goals with continuous commitment and enthusiasm.

NMS Group is the largest company in Italy committed in innovation and research and development in oncology.

About us

Our company is a high value organization covering the whole R&D process: from pre-clinical phase of research, to First-Time-In-Man of clinical phase, up to production and packaging of the finished drug. Nerviano Medical Sciences represents the innovative heart of the Group and make it an important and international reference in the field of personalized therapy. NMS Group also provides Research and Production services, addressed to local and international markets through three different companies: Accelera, one of the few companies engaged in preclinical research in Italy; Clioss engaged in clinical development starting from First-Time-In-Man and Nerpharma, dealing with activities from formulation to production of the active principle.

Our numbers

About us

Active patents and
patent applications
Pre clinical
Overall worldwide collaborations with research & care Centers

Media Press & News >

Nerviano, 03.04.2019

At AACR meeting Nerviano Medical Sciences presents new evidences on its own FLT3/KIT/CSF1R inhibitor and its activities on the identification and characterization of ATP-mimetic choline kinase inhibitors.

These new activities and evidences come from the Kinase platform in Nerviano Medical Sciences, an integrated system of know-how, technologies and intellectual property developed over the years that allows the research Campus a conspicuous synergy in the efficient development of innovative anticancer drugs.
Read more +